Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $23.00.

STOK has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Chardan Capital reissued a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 in the last three months. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Barclays PLC boosted its stake in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares during the last quarter. Geode Capital Management LLC boosted its position in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares during the last quarter. State Street Corp boosted its position in Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares during the last quarter. RTW Investments LP grew its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after acquiring an additional 71,647 shares during the last quarter.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $8.15 on Friday. The stock has a market capitalization of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $5.93 and a 1 year high of $17.58. The company’s fifty day moving average is $9.47 and its two-hundred day moving average is $11.45.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Sell-side analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.